Top Stories
The company said its two proprietary technologies, one built on antibodies and the other on lipid nanoparticles, work in complementary ways to press the immune system's reset button.
Ortet is focused on improving personalised healthcare.
Egetis Therapeutics' Emcitate is approved to treat peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency.
The update on ifezuntirgene inilparvovec, which is currently under review by the FDA, sent the company's shares down as much as 56% in pre-market trading.
The company's lead asset, danegaptide, works by stabilising the retinal vasculature, thus protecting against retinal capillary breakdown and vascular leakage caused by hyperglycaemia.
Conference News
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a ma...
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patientsReal-world evidence from mor...
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today anno...
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 4842% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing ...
